Table 1. 2005 WHO guidelines: antimicrobials for treatment of shigellosis (adapted) [4].
Antimicrobial | Treatment schedule for children | Limitations |
---|---|---|
1st-line: ciprofloxacin | 15 mg/kg orally twice daily for 3 days | Expensive |
Resistance emerging | ||
Drug interactions | ||
2nd-line: pivmecillinam | 20 mg/kg orally 4 times daily for 5 days | Cost |
No paediatric formulation | ||
Four times daily dosing | ||
Resistance emerging | ||
OR*: ceftriaxone | 50–100 mg/kg intramuscular injection for 2–5 days | Requires parenteral administration |
Generates antimicrobial resistance | ||
OR: (for adults) azithromycin | 6–20 mg/kg, orally once daily for 1–5 days | Cost |
Drug interactions | ||
Resistance emerges rapidly, spreads to other bacteria |
Ceftriaxone is listed as an alternative therapy ‘only for use when local strains of shigella are known to be resistant to ciprofloxacin’.